Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


12 Nov 2016 - 16 Nov 2016
16 Nov 2016 - 19 Nov 2016

X-Ray Imaging System Enables Scientists to See in Real Time How Effective Treatments are for Cystic Fibrosis

By BiotechDaily International staff writers
Posted on 25 Aug 2014
Print article
Image: Dr. Kaye Morgan, Monash University (Photo courtesy of Monash University).
Image: Dr. Kaye Morgan, Monash University (Photo courtesy of Monash University).
A new imaging approach allows researchers to monitor the effectiveness of a treatment for the life-threatening genetic disorder.

Cystic fibrosis affects many of the body’s systems, but most severely the lungs, and currently it can take several months to measure how effective treatment is for the early-fatal lung disease.

Dr. Kaye Morgan, from Monash University (Melbourne; VIC, Australia), and lead researcher of the study, reported that the new X-ray imaging strategy allows researchers to visualize soft tissue structures, for example, the airways, brain, and lungs, which are effectively hidden in standard X-ray images. “At the moment we typically need to wait for a cystic fibrosis treatment to have an effect on lung health, measured by either a lung CT [computed tomography] scan or breath measurement, to see how effective that treatment is,” Dr. Morgan said. “However the new imaging technique allows us for the first time to noninvasively see how the treatment is working ‘live’ on the airway surface.”

Dr. Morgan noted that this X-ray imaging method would enable clinicians and researchers to measure how effective treatments are, and progress new treatments to the clinic at a much quicker rate, a key goal of the investigators. “Because we will be able to see how effectively treatments are working straight away, we’ll be able to develop new treatments a lot more quickly, and help better treat people with cystic fibrosis,” Dr. Morgan said.

Dr. Morgan noted that the new imaging technology, which was developed using a synchrotron X-ray source, may also create new avenues for assessing how effective treatments were for other lung, heart, and brain diseases.

The study’s findings were published August 15, 2014, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:

Monash University

Print article


Drug Discovery

view channel
Image: Positive alpha-synuclein staining of a Lewy body from a patient with Parkinson\'s disease (Photo courtesy of Wikimedia Commons).

Bifunctional Dimer Drugs Prove Effective in Parkinson's Disease Yeast Model

A team of Canadian neurodegenerative disease researchers used a yeast model system to identify novel drug compounds that were able to block the misfolding of alpha- synuclein (AS) protein, which characterizes... Read more


view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more


view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.